EPI-321 is an investigational AAV-delivered epigenetic gene-editing therapy developed by Epicrispr Biotechnologies for the treatment of facioscapulohumeral muscular dystrophy (FSHD) type 1. The therapy uses a non-cutting CRISPR-based epigenetic editor (dCasONYX) fused to methylation-modulating domains to selectively re-methylate the D4Z4 repeat region near the DUX4 gene, thereby repressing pathogenic DUX4 expression without introducing DNA double-strand breaks. EPI-321 is delivered as a single intravenous infusion using a muscle-tropic AAVrh74 vector under a muscle-specific promoter.
Disease: Facioscapulohumeral Muscular Dystrophy, (NCT06907875)
To see all details you need to have a subscription token. Click here for more details
Candidate summary:
Disease/Disease category:
- Neuromuscular diseases
Official title:
A Phase 1/2 Open-label Dose-escalation Study to Evaluate the Safety, Tolerability, and Biological Activity of EPI-321, an AAVrh74-delivered Epigenetic Editing Therapy in Adult FSHD Patients
Phases:
- Phase 1
- Phase 2
Status:
Active recruiting
Country:
- United States
- Australia
- New Zealand